Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells.

@article{Lunghi2004TreatmentWA,
  title={Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells.},
  author={Paolo Lunghi and Antonio Costanzo and Massimo Levrero and Antonio Bonati},
  journal={Blood},
  year={2004},
  volume={104 2},
  pages={
          519-25
        }
}
Arsenic trioxide (ATO) induces differentiation and apoptosis of malignant cells in vitro and in vivo and has been used in the treatment of a variety of hematologic malignancies. We found that in NB4 acute promyelocytic and in K562 erythroleukemia cell lines treatment with the MEK1 inhibitors PD98059 and PD184352 greatly enhances apoptotic cell death induced by ATO alone. Combined treatment results in the induction of the p53AIP1 (p53-regulated apoptosis-inducing protein 1) gene in both cell… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 60 references

Mitogen-activated protein kinase is involved in the 524

  • X Song, HM Sheppard, AW Norman, X. Liu
  • LUNGHI et al BLOOD,
  • 2004

blasts

  • M Milella, SM Kornblau, Z Estrov
  • 2003

Similar Papers

Loading similar papers…